Special Announcement - December 8, 2011
Position Statement on ST-246 Procurement Contract - Download Here
We are aware of news reports suggesting that there are reasons for concern regarding our contract with BARDA to supply smallpox antiviral to the Strategic National Stockpile. We believe all such concerns to be unfounded and based on misinformation. The link above will take you to a statement of our position on these issues, prepared by our Chairman and Chief Executive Officer, Dr. Eric A. Rose. Dr. Rose explains the need for ST-246®, its value and how the acquisition process actually worked, in accordance with all governing standards. We urge our shareholders and all other interested parties to download this statement.
Welcome to SIGA Technologies
At SIGA, we specialize in developing therapeutic solutions for some of the most lethal disease-causing pathogens - smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. Our business is to discover, develop, manufacture and successfully commercialize drugs to prevent and treat these high-priority threats.
Highlighted Activities
SIGA’s lead compound, ST-246® (Tecovirimat), is a novel drug under development for the treatment of smallpox – a potential bioterrorism threat. Procurement of this drug will transition SIGA to a commercial-stage company and support development of our other drug candidates.